Search

Your search keyword '"Perla, F"' showing total 9 results
Start Over Author "Perla, F" Topic business
9 results on '"Perla, F"'

1. The Italian multiple sclerosis register

Author

Trojano, M, Bergamaschi, R, Amato, Mp, Comi, G, Ghezzi, A, Lepore, V, 7, Marrosu, Mg, Mosconi, P, Patti, F, Ponzio, M, Zaratin, P, Battaglia, Ma1, Acquistapace D, Italian Multiple Sclerosis Register Centers Group., Aguglia, U, Annunziata, P, Ardito, B, Avolio, C, Balgera, R, Bandini, F, Banfi, P, Barone, P, Bellantonio, P, Bertolotto, A, Bertora, P, Bombardi, R, Bosco Zimatore, G, Bossio, Rb, Bramanti, P, Brescia Morra, V, Brioschi, Am, Bruzzone, M, Buccafusca, M, Busillo, V, Caneve, G, Caniatti, Lm, Capone, L, Capone, F, Cappellani, A, Cargnelutti, D, Cavaletti, G, Cavalla, P, Celani, Mg, Centonze, D, Chiveri, L, Clerici, R, Clerico, M, Cocco, E, Comi, C, Coniglio, Mg, Cordera, S, Corea, F, Cortese, A, Costantino, G, Cottone, S, Crociani, P, D'Andrea, F, Danni, Mc, De Luca, G, de Pascalis, D, De Robertis, F, De Stefano, N, Di Battista, G, Di Napoli, M, Falcini, M, Fausto, F, Ferrò, Mt, Florio, C, Fortunato, M, Frittelli, C, Galgani, S, Gallo, P, Gatto, M, Gazzola, P, Geda, C, Giordano, A, Granella, F, Grasso, Mg, Grimaldi, Lme, Imperiale, D, Lo Russo, L, Logullo, Fo, Lugaresi, A, Lus, G, Maccarrone, G, Maimone, D, Malagù, S, Marconi, R, Maritato, P, Massacesi, L, Mazzoni, M, Meucci, G, Mirabella, M, Montepietra, S, Nasuelli, D, Neri, W, Orefice, G, Parodi, S, Pasquali, L, Passarella, B, Peresson, M, Perla, F, Pesci, I, Piantadosi, C, Piras, Ml, Pizio, Nr, Pozzilli, C, Protti, A, Pugliatti, M, Quatrale, R, Ragno, M, Rezzonico, M, Ribizzi, G, Riva, M, Ronzoni, M, Rosso, Mg, Rottoli, M, Rovaris, M, Salemi, G, Salvetti, M, Santangelo, M, Santangelo, G, Santuccio, G, Sarchielli, P, Scarpini, E, Sechi, Gp, Severi, S, Sinisi, L, Sola, P, Spitaleri, D, Tassinari, T, Tedeschi, G, Tonietti, S, Torri Clerici, V, Totaro, R, Traccis, S, Turla, M, Uccelli, A, Ulivelli, M, Valentino, P, Valeriani, M, Venturi, S, Vianello, M, Zaffaroni, M., Trojano M., Bergamaschi R., Amato M.P., Comi G., Ghezzi A., Lepore V., Marrosu M.G., Mosconi P., Patti F., Ponzio M., Zaratin P., Battaglia M.A., Acquistapace D., Aguglia U., Annunziata P., Ardito B., Avolio C., Balgera R., Bandini F., Banfi P., Barone P., Bellantonio P., Bertolotto A., Bertora P., Bombardi R., Bosco Zimatore G., Bossio R.B., Bramanti P., Brescia Morra V., Brioschi A.M., Bruzzone M., Buccafusca M., Busillo V., Caneve G., Caniatti L.M., Capone L., Capone F., Cappellani A., Cargnelutti D., Cavaletti G., Cavalla P., Celani M.G., Centonze D., Chiveri L., Clerici R., Clerico M., Cocco E., Comi C., Coniglio M.G., Cordera S., Corea F., Cortese A., Costantino G., Cottone S., Crociani P., D'Andrea F., Danni M.C., De Luca G., de Pascalis D., De Robertis F., De Stefano N., Di Battista G., Di Napoli M., Falcini M., Fausto F., Ferro M.T., Florio C., Fortunato M., Frittelli C., Galgani S., Gallo P., Gatto M., Gazzola P., Geda C., Giordano A., Granella F., Grasso M.G., Grimaldi L.M.E., Imperiale D., Lo Russo L., Logullo F.O., Lugaresi A., Lus G., Maccarrone G., Maimone D., Malagu S., Marconi R., Maritato P., Massacesi L., Mazzoni M., Meucci G., Mirabella M., Montepietra S., Nasuelli D., Neri W., Orefice G., Parodi S., Pasquali L., Passarella B., Peresson M., Perla F., Pesci I., Piantadosi C., Piras M.L., Pizio N.R., Pozzilli C., Protti A., Pugliatti M., Quatrale R., Ragno M., Rezzonico M., Ribizzi G., Riva M., Ronzoni M., Rosso M.G., Rottoli M., Rovaris M., Salemi G., Salvetti M., Santangelo M., Santangelo G., Santuccio G., Sarchielli P., Scarpini E., Sechi G.P., Severi S., Sinisi L., Sola P., Spitaleri D., Tassinari T., Tedeschi G., Tonietti S., Torri Clerici V., Totaro R., Traccis S., Turla M., Uccelli A., Ulivelli M., Valentino P., Valeriani M., Venturi S., Vianello M., Zaffaroni M., Trojano M, Bergamaschi R, Amato M.P, Comi G, Ghezzi A, Lepore V, Marrosu M.G, Mosconi P, Patti F, Ponzio M, Zaratin P, Battaglia M.A, Acquistapace D., Aguglia U., Annunziata P., Ardito B., Avolio C., Balgera R., Bandini F., Banfi P., Barone P., Bellantonio P., Bertolotto A., Bertora P., Bombardi R., Bosco Zimatore G., Bossio R.B., Bramanti P., Brescia Morra V., Brioschi A.M., Bruzzone M., Buccafusca M., Busillo V., Caneve G., Caniatti L.M., Capone L., Capone F., Cappellani A., Cargnelutti D., Cavaletti G., Cavalla P., Celani M.G., Centonze D., Chiveri L., Clerici R., Clerico M., Cocco E., Comi C., Coniglio M.G., Cordera S., Corea F., Cortese A., Costantino G., Cottone S., Crociani P., D’Andrea F., Danni M.C., De Luca G., de Pascalis D., De Robertis F., De Stefano N., Di Battista G., Di Napoli M., Falcini M., Fausto F., Ferrò M.T., Florio C., Fortunato M., Frittelli C., Galgani S., Gallo P., Gatto M., Gazzola P., Geda C., Giordano A., Granella F., Grasso M.G., Grimaldi L.M.E., Imperiale D., Lo Russo L., Logullo F.O., Lugaresi A., Lus G., Maccarrone G., Maimone D., Malagù S., Marconi R., Maritato P., Massacesi L., Mazzoni M., Meucci G., Mirabella M., Montepietra S., Nasuelli D., Neri W., Orefice G., Parodi S., Pasquali L., Passarella B., Peresson M., Perla F., Pesci I., Piantadosi C., Piras M.L., Pizio N.R., Pozzilli C., Protti A., Pugliatti M., Quatrale R., Ragno M., Rezzonico M., Ribizzi G., Riva M., Ronzoni M., Rosso M.G., Rottoli M., Rovaris M., Salemi G., Salvetti M., Santangelo M., Santangelo G., Santuccio G., Sarchielli P., Scarpini E., Sechi G.P., Severi S., Sinisi L., Sola P, Spitaleri D., Tassinari T., Tedeschi G., Tonietti S., Torri Clerici V., Totaro R., Traccis S., Turla M., Uccelli A., Ulivelli M., Valentino P., Valeriani M., Venturi S., Vianello M., Zaffaroni M., Trojano, Maria, Bergamaschi, Roberto, Amato, Maria Pia, Comi, Giancarlo, Ghezzi, Angelo, Lepore, Vito, Marrosu, Maria Giovanna, Mosconi, Paola, Patti, Francesco, Ponzio, Michela, Zaratin, Paola, Battaglia, Mario Alberto, Acquistapace, D, Aguglia, U, Amato, Mp, Annunziata, P, Ardito, B, Avolio, C, Balgera, R, Bandini, F, Banfi, P, Barone, P, Bellantonio, P, Bergamaschi, R, Bertolotto, A, Bertora, P, Bombardi, R, Bosco Zimatore, G, Bossio, Rb, Bramanti, P, Brescia Morra, V, Brioschi, Am, Bruzzone, M, Buccafusca, M, Busillo, V, Caneve, G, Caniatti, Lm, Capone, L, Capone, F, Cappellani, A, Cargnelutti, D, Cavaletti, G, Cavalla, P, Celani, Mg, Centonze, D, Chiveri, L, Clerici, R, Clerico, M, Cocco, E, Comi, G, Comi, C, Coniglio, Mg, Cordera, S, Corea, F, Cortese, A, Costantino, G, Cottone, S, Crociani, P, D'Andrea, F, Danni, Mc, De Luca, G, de Pascalis, D, De Robertis, F, De Stefano, N, Di Battista, G, Di Napoli, M, Falcini, M, Fausto, F, Ferrò, Mt, Florio, C, Fortunato, M, Frittelli, C, Galgani, S, Gallo, P, Gatto, M, Gazzola, P, Geda, C, Giordano, A, Granella, F, Grasso, Mg, Grimaldi, Lme, Imperiale, D, Lo Russo, L, Logullo, Fo, Lugaresi, A, Lus, G, Maccarrone, G, Maimone, D, Malagù, S, Marconi, R, Maritato, P, Massacesi, L, Mazzoni, M, Meucci, G, Mirabella, M, Montepietra, S, Nasuelli, D, Neri, W, Orefice, G, Parodi, S, Pasquali, L, Passarella, B, Patti, F, Peresson, M, Perla, F, Pesci, I, Piantadosi, C, Piras, Ml, Pizio, Nr, Pozzilli, C, Protti, A, Pugliatti, M, Quatrale, R, Ragno, M, Rezzonico, M, Ribizzi, G, Riva, M, Ronzoni, M, Rosso, Mg, Rottoli, M, Rovaris, M, Salemi, G, Salvetti, M, Santangelo, M, Santangelo, G, Santuccio, G, Sarchielli, P, Scarpini, E, Sechi, Gp, Severi, S, Sinisi, L, Sola, P, Spitaleri, D, Tassinari, T, Tedeschi, G, Tonietti, S, Torri Clerici, V, Totaro, R, Traccis, S, Trojano, M, Turla, M, Uccelli, A, Ulivelli, M, Valentino, P, Valeriani, M, Venturi, S, Vianello, M, Zaffaroni, M., Amato, M, Ghezzi, A, Lepore, V, Marrosu, M, Mosconi, P, Ponzio, M, Zaratin, P, Battaglia, M, Bossio, R, Brioschi, A, Caniatti, L, Celani, M, Coniglio, M, D’Andrea, F, Danni, M, Ferrò, M, Grasso, M, Grimaldi, L, Logullo, F, Piras, M, Pizio, N, Rosso, M, Sechi, G, and Zaffaroni, M

Subjects
Register (sociolinguistics), Adult, Male, Knowledge management, Databases, Factual, Epidemiology, media_common.quotation_subject, Disease epidemiology, Multiple sclerosis, Quality of care, Register, Longitudinal Studie, Dermatology, NO, Cohort Studies, Databases, 03 medical and health sciences, 0302 clinical medicine, Multiple Sclerosi, Humans, Quality (business), Longitudinal Studies, 030212 general & internal medicine, Registries, Epidemiology, Multiple sclerosis, Quality of care, Register, Adult, Cohort Studies, Data Collection, Databases, Factual, Female, Humans, Italy, Longitudinal Studies, Male, Multiple Sclerosis, Registries, Factual, media_common, Data collection, business.industry, Data Collection, Correction, Female, Italy, Multiple Sclerosis, General Medicine, Register data, Psychiatry and Mental Health, Observational study, Original Article, Settore MED/26 - Neurologia, Business, Neurology (clinical), Cohort Studie, 030217 neurology & neurosurgery, 2708, Human
Abstract

The past decade has seen extraordinary increase in worldwide availability of and access to several large multiple sclerosis (MS) databases and registries. MS registries represent powerful tools to provide meaningful information on the burden, natural history, and long-term safety and effectiveness of treatments. Moreover, patients, physicians, industry, and policy makers have an active interest in real-world observational studies based on register data, as they have the potential to answer the questions that are most relevant to daily treatment decision-making. In 2014, the Italian MS Foundation, in collaboration with the Italian MS clinical centers, promoted and funded the creation of the Italian MS Register, a project in continuity with the existing Italian MS Database Network set up from 2001. Main objective of the Italian MS Register is to create an organized multicenter structure to collect data of all MS patients for better defining the disease epidemiology, improving quality of care, and promoting research projects in high-priority areas. The aim of this article is to present the current framework and network of the Italian MS register, including the methodology used to improve the quality of data collection and to facilitate the exchange of data and the collaboration among national and international groups. The past decade has seen extraordinary increase in worldwide availability of and access to several large multiple sclerosis (MS) databases and registries. MS registries represent powerful tools to provide meaningful information on the burden, natural history, and long-term safety and effectiveness of treatments. Moreover, patients, physicians, industry, and policy makers have an active interest in real-world observational studies based on register data, as they have the potential to answer the questions that are most relevant to daily treatment decision-making. In 2014, the Italian MS Foundation, in collaboration with the Italian MS clinical centers, promoted and funded the creation of the Italian MS Register, a project in continuity with the existing Italian MS Database Network set up from 2001. Main objective of the Italian MS Register is to create an organized multicenter structure to collect data of all MS patients for better defining the disease epidemiology, improving quality of care, and promoting research projects in high-priority areas. The aim of this article is to present the current framework and network of the Italian MS register, including the methodology used to improve the quality of data collection and to facilitate the exchange of data and the collaboration among national and international groups.

Published
2019

2. American trypanosomiasis and Chagas disease: Sexual transmission

Author

Adriana B. Almeida, Antonio R. L. Teixeira, Clever C. Gomes, Perla F. Araujo, and Ana C. Rosa

Subjects
0301 basic medicine, Microbiology (medical), Chagas disease, Male, medicine.medical_specialty, Sexual transmission, 030106 microbiology, Sexually Transmitted Diseases, Prenatal care, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, 0302 clinical medicine, Environmental health, Epidemiology, parasitic diseases, medicine, Humans, lcsh:RC109-216, Chagas Disease, 030212 general & internal medicine, Trypanosoma cruzi, Travel, biology, business.industry, Transmission (medicine), Public health, Research, Neglected Disease, Neglected Diseases, Prenatal Care, General Medicine, medicine.disease, biology.organism_classification, Infectious Diseases, Latin America, Female, business
Abstract

Objective: To contribute to the discussion on the research findings indicating the sexual transmission of American trypanosomiasis and Chagas disease in humans. Methods: A review of the literature was performed to investigate the routes of transmission of Trypanosoma cruzi parasites and to evaluate the distribution of Chagas disease, which is now found across five continents. Results: The epidemiological profile of American trypanosomiasis, which is still considered a neglected disease of the poor people of Latin America, has changed over time. A family-based study demonstrated that the blood protozoan T. cruzi can be transmitted sexually from infected males and females to naïve mates. Conclusions: Evidence that Chagas disease can be transmitted sexually, coupled with the migration of individuals with Chagas disease to previously non-endemic countries and increased travel to endemic countries, has implications for public health. Improved screening of blood supplies and prenatal care are required to prevent congenital spread. Keywords: Trypanosoma cruzi, Chagas disease, Sexual transmission, Humans, Mouse model system, Vertical transmission, Diagnosis, Prevention

Published
2018

3. A Multicentric Prospective Incidence Study of Guillain-Barré Syndrome in Italy. The ITANG Study

Author

Benedetti, M, Pugliatti, M, Dalessandro, R, BEGHI, ETTORE, Chiò, A, Logroscino, G, Filippini, G, Galeotti, F, Massari, M, Santuccio, C, Raschetti, R, Abruzzi, L, Agazzi, E, Agostoni, E, Ambrogio, L, Amidei, S, Arbasino, C, Argentiero, V, Arnaboldi, M, Baldini, D, Barki, R, Bassi, P, Basso, F, Belcastro, V, Bellotti, M, Bersano, E, Besana, R, Bettoni, L, Bezzi, G, Bianconi, C, Bondavalli, M, Bonometti, A, Borghi, AM, Borsato, C, Bortolotto, S, Bottacchi, EF, Bresolin, N, Bruno, S, Burlina, A, Cafasso, G, Callegarini, C, Calvo, A, Candeloro, E, Casano, A, Cattaneo, SI, Cavallo, R, Cheldi, A, Ciardo, G, Cirignotta, F, Clerici, AM, Clerici, R, Comi, G, Conti, R, Coppo, F, Covelli, V, Crespi, V, Currò Dossi, M, Curtò, NA, D'Adda, E, Dallocchio, C, D'Anna, S, De Massis, P, De Toni Franceschini, L, Di Vito, N, Didonè, G, Dileone, M, Donati, E, Dotta, M, Fazio, R, Federico, F, FERRARESE, CARLO, Ferrazzini, F, Ferrero, B, Filosto, M, Frasson, E, Fusina, S, Galbussera, A, Gastaldo, E, Geda, C, Ghiglione, P, Giometto, B, Gionco, M, Giorgetti, A, Giussani, G, Gobbin, F, Grampa, G, Granieri, E, Greco, G, Guidetti, D, Guidi, C, Guidotti, M, Gusmaroli, G, Imperiale, D, Internò, S, Jann, S, La Spina, I, Leo, A, Leone, M, Leoni, S, Leotta, D, Lerario, R, Liotta, G, Livrea, P, Luda di Cortemiglio, E, Maggio, B, Magni, E, Magnoni, A, Maistrelli, J, Manca, D, Mandrioli, J, Manera, U, Marcello, N, Marchi, P, Marchini, C, Marconi, S, Mattioli, M, Mauro, A, Mazzaglia, G, Medici, D, Meineri, P, Meola, G, Micaglio, G, Michelucci, R, Michieli, G, Micieli, G, Minardi, C, Moglia, C, Monaco, S, Montanari, E, Moretto, G, Munerati, V, Mura, G, Mussutto, V, Nascimbene, C, Neri, W, Nichelli, P, Nobile Orazio, E, Oddenino, E, Onorato, S, Padovani, A, Palermo, M, Papurello, DM, Passarella, B, Pavesi, G, Penza, MT, Perini, M, Perini, F, Perla, F, Perlotto, N, Perrone, P, Pignatta, P, Pisano, F, Poglio, F, Polo, A, Poloni, M, Porazzi, D, Pradotto, L, Previdi, P, Quatrale, R, Rasi, F, Ravasio, A, Ravetti, C, Repaci, M, Riccardi, T, Riguzzi, P, Rinaldi, R, Riva, M, Romeo, V, Romorini, A, Rosso, T, Rotondo, G, Sacquegna, T, Sanson, F, Santamato, V, Santoro, D, Sartori, V, Sasanelli, F, Savio, K, Serena, M, Silani, V, Silvestri, L, Simioni, V, Squintani, GM, Suardelli, M, Tartagla, L, Terenghi, F, Terlizzi, E, Terzano, M, Tesser, F, Testa, L, Ticca, A, Ticozzi, N, Tiriticco, M, Tola, MR, Tonietti, S, Trianni, G, Trojano, M, Trotta, F, Turatti, M, Ursino, E, Vanotti, A, Vercellino, M, Villani, A, Vitelli, E, Zambito Marsala, S, Zanette, G, Zarcone, D, Zimatore, G, Zoccolella, S., Benedetti, Md, Pugliatti, M, D'Alessandro, R, Beghi, E, Chiò, A, Logroscino, G, Filippini, G, Galeotti, F, Massari, M, Santuccio, C, Comi, Giancarlo, Raschetti, R, ITANG Study, Group, Giometto, B, Benedetti, M, Dalessandro, R, Abruzzi, L, Agazzi, E, Agostoni, E, Ambrogio, L, Amidei, S, Arbasino, C, Argentiero, V, Arnaboldi, M, Baldini, D, Barki, R, Bassi, P, Basso, F, Belcastro, V, Bellotti, M, Bersano, E, Besana, R, Bettoni, L, Bezzi, G, Bianconi, C, Bondavalli, M, Bonometti, A, Borghi, A, Borsato, C, Bortolotto, S, Bottacchi, E, Bresolin, N, Bruno, S, Burlina, A, Cafasso, G, Callegarini, C, Calvo, A, Candeloro, E, Casano, A, Cattaneo, S, Cavallo, R, Cheldi, A, Ciardo, G, Cirignotta, F, Clerici, A, Clerici, R, Comi, G, Conti, R, Coppo, F, Covelli, V, Crespi, V, Currò Dossi, M, Curtò, N, D'Adda, E, Dallocchio, C, D'Anna, S, De Massis, P, De Toni Franceschini, L, Di Vito, N, Didonè, G, Dileone, M, Donati, E, Dotta, M, Fazio, R, Federico, F, Ferrarese, C, Ferrazzini, F, Ferrero, B, Filosto, M, Frasson, E, Fusina, S, Galbussera, A, Gastaldo, E, Geda, C, Ghiglione, P, Gionco, M, Giorgetti, A, Giussani, G, Gobbin, F, Grampa, G, Granieri, E, Greco, G, Guidetti, D, Guidi, C, Guidotti, M, Gusmaroli, G, Imperiale, D, Internò, S, Jann, S, La Spina, I, Leo, A, Leone, M, Leoni, S, Leotta, D, Lerario, R, Liotta, G, Livrea, P, Luda di Cortemiglio, E, Maggio, B, Magni, E, Magnoni, A, Maistrelli, J, Manca, D, Mandrioli, J, Manera, U, Marcello, N, Marchi, P, Marchini, C, Marconi, S, Mattioli, M, Mauro, A, Mazzaglia, G, Medici, D, Meineri, P, Meola, G, Micaglio, G, Michelucci, R, Michieli, G, Micieli, G, Minardi, C, Moglia, C, Monaco, S, Montanari, E, Moretto, G, Munerati, V, Mura, G, Mussutto, V, Nascimbene, C, Neri, W, Nichelli, P, Nobile Orazio, E, Oddenino, E, Onorato, S, Padovani, A, Palermo, M, Papurello, D, Passarella, B, Pavesi, G, Penza, M, Perini, M, Perini, F, Perla, F, Perlotto, N, Perrone, P, Pignatta, P, Pisano, F, Poglio, F, Polo, A, Poloni, M, Porazzi, D, Pradotto, L, Previdi, P, Quatrale, R, Rasi, F, Ravasio, A, Ravetti, C, Repaci, M, Riccardi, T, Riguzzi, P, Rinaldi, R, Riva, M, Romeo, V, Romorini, A, Rosso, T, Rotondo, G, Sacquegna, T, Sanson, F, Santamato, V, Santoro, D, Sartori, V, Sasanelli, F, Savio, K, Serena, M, Silani, V, Silvestri, L, Simioni, V, Squintani, G, Suardelli, M, Tartagla, L, Terenghi, F, Terlizzi, E, Terzano, M, Tesser, F, Testa, L, Ticca, A, Ticozzi, N, Tiriticco, M, Tola, M, Tonietti, S, Trianni, G, Trojano, M, Trotta, F, Turatti, M, Ursino, E, Vanotti, A, Vercellino, M, Villani, A, Vitelli, E, Zambito Marsala, S, Zanette, G, Zarcone, D, Zimatore, G, and Zoccolella, S

Subjects
Adult, Male, Pediatrics, medicine.medical_specialty, Epidemiology, Population, Guillain-Barre Syndrome, Rate ratio, NO, Young Adult, Axonal and demyelinating GBS, Guillain-Barré syndrome, Incidence, Prospective study, Trend, Neurology (clinical), Aged, Aged, 80 and over, Female, Humans, Italy, Middle Aged, 80 and over, medicine, Young adult, education, Prospective cohort study, education.field_of_study, Guillain-Barre syndrome, business.industry, Medicine (all), Incidence (epidemiology), medicine.disease, Vaccination, Settore MED/26 - NEUROLOGIA, business, Human
Abstract

Background: To assess Guillain-Barré syndrome (GBS) incidence we relied on the Italian Network for the study of GBS (ITANG) established in 2010 in 7 Italian regions to analyse the association between influenza vaccination and GBS. Methods: All individuals aged ≥18 years, presenting with clinical manifestations that suggested GBS according to the universally accepted Asbury's diagnostic criteria (1990) were prospectively notified to a centralised database by ITANG neurologists over the period October 1, 2010-September 30, 2011. Through a telephone survey, 9 trained interviewers followed up the cases to diagnosis and then for 1 year since hospital discharge. Validation of case reporting was performed with the support of administrative data in 5 regions. Results: We found 365 cases fulfilling the definition for GBS or one of its variants over 19,846,068 population ≥18 years of age, yielding an annual incidence rate of 1.84 per 100,000 (95% CI 1.65-2.03), 2.30 (95% CI 1.99-2.60) in men and 1.41 (95% CI 1.18-1.64) in women. A highly significant peak of incidence was observed in February 2011 as compared to reference month (September 2011, rate ratio 3.3:1, p < 0.01). Conclusions: In Italy, GBS incidence was among the highest reported in Europe and higher than previously observed in Italian studies.

Published
2015

4. Genetic burden of common variants in progressive and bout-onset multiple sclerosis

Author

SOROSINA M, BRAMBILLA P, CLARELLI F, BARIZZONE N, LUPOLI S, GUASCHINO C, OSICEANU AM, MOIOLA L, GHEZZI A, CONIGLIO G, PATTI F, MANCARDI G, MANUNTA P, GLORIOSO N, GUERINI FR, BERGAMASCHI R, PERLA F, PROGRESSO, PROGEMUS, MARTINELLI V, CUSI D, LEONE M, COMI G, D'ALFONSO S, MARTINELLI BONESCHI F, Among the collaborators, TEDESCHI, Gioacchino, Sorosina, M, Brambilla, P, Clarelli, F, Barizzone, N, Lupoli, S, Guaschino, C, Osiceanu, Am, Moiola, L, Ghezzi, An, Coniglio, G, Patti, F, Mancardi, G, Manunta, P, Glorioso, N, Guerini, Fr, Bergamaschi, R, Perla, F, Martinelli, V, Cusi, D, Leone, M, Comi, G, D’Alfonso, S, MARTINELLI-BONESCHI, F, PROGRESSO STUDY, Group, PROGEMUS STUDY, Group, Ghezzi, A, Progresso, Progemu, D'Alfonso, S, MARTINELLI BONESCHI, F, D'Ambrosio, Alessandro, and Tedeschi, Gioacchino

Subjects
Oncology, Male, Genome-wide association study, Sex Factor, Disease, Heritability, Multiple sclerosis, Primary progressive, Relapsing-remitting, Adolescent, Adult, Aged, Aged, 80 and over, Female, Genetic Markers, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Italy, Magnetic Resonance Imaging, Middle Aged, Multiple Sclerosis, Chronic Progressive, Phenotype, Risk Factors, Sex Factors, Young Adult, Polymorphism, Single Nucleotide, Neurology, Neurology (clinical), Genetic Marker, 80 and over, Genetic risk, Genetics, Multiple Sclerosis, Chronic Progressive, Explained variation, Human, medicine.medical_specialty, Single-nucleotide polymorphism, Polymorphism, Single Nucleotide, Internal medicine, medicine, Multiple sclerosi, business.industry, Risk Factor, medicine.disease, business
Abstract

Background: The contribution of genetic variants underlying the susceptibility to different clinical courses of multiple sclerosis (MS) is still unclear. Objective: The aim of the study is to evaluate and compare the proportion of liability explained by common SNPs and the genetic burden of MS-associated SNPs in progressive onset (PrMS) and bout-onset (BOMS) cases. Methods: We estimated the proportion of variance in disease liability explained by 296,391 autosomal SNPs in cohorts of Italian PrMS and BOMS patients using the genome-wide complex trait analysis (GCTA) tool, and we calculated a weighted genetic risk score (wGRS) based on the known MS-associated loci. Results: Our results identified that common SNPs explain a greater proportion of phenotypic variance in BOMS (36.5%±10.1%) than PrMS (20.8%±6.0%) cases, and a trend of decrease was observed when testing primary progressive (PPMS) without brain MRI inflammatory activity ( p = 7.9 × 10−3). Similarly, the wGRS and the variance explained by MS-associated SNPs were higher in BOMS than PPMS in males (wGRS: 6.63 vs 6.51, p = 0.04; explained variance: 4.8%±1.5% vs 1.7%±0.6%; p = 0.05). Conclusions: Our results suggest that the liability of disease is better captured by common genetic variants in BOMS than PrMS cases. The absence of inflammatory activity and male gender further raise the difference between clinical courses.

Published
2014

5. First on-line survey of an international multidisciplinary working group (MightyMedic) on current practice in diagnosis, therapy and follow-up of dyslipidemias

Author

Stefanutti, C, D'Alessandri, G, Petta, A, Harada-Shiba, M, Julius, U, Soran, H, Moriarty, P. M, Romeo, S, Drogari, E, Jaeger, B. R, Bianciardi, G, Bosco, G, Cossu, M, De Fusco, G, Di Giacomo, S, Ewald, N, Gualdi, G, Lanti, A, Marson, P, Martino, F, Migliori, G, Parasassi, T, Pavan, A, Perla, F. M, Perrone, G, Pisciotta, L, Renga, S, Ries, W, and Romano, N

Subjects
medicine.medical_specialty, Time Factors, International Cooperation, Practice Patterns, Coronary artery disease, Dyslipidemia, Lipoprotein apheresis, Multicenter study, Survey, Biomarkers, Blood Component Removal, Cardiovascular Diseases, Cooperative Behavior, Dyslipidemias, Guideline Adherence, Health Care Surveys, Humans, Hypolipidemic Agents, Lipids, Molecular Diagnostic Techniques, Practice Guidelines as Topic, Practice Patterns, Physicians', Predictive Value of Tests, Risk Factors, Surveys and Questionnaires, Treatment Outcome, Internet, Internal Medicine, Cardiology and Cardiovascular Medicine, Multidisciplinary approach, medicine, Parallel field, Therapeutic apheresis, Physicians', business.industry, General Medicine, medicine.disease, Clinical trial, Current practice, Family medicine, Physical therapy, business
Abstract

The MightyMedic (Multidisciplinary International Group for Hemapheresis TherapY and MEtabolic DIsturbances Contrast) Working Group has been founded in 2013. The leading idea was to establish an international network of interdisciplinary nature aimed at working to cross national borders research projects, clinical trials, educational initiatives (meetings, workshops, summer schools) in the field of metabolic diseases, namely hyperlipidemias, and diabetes, preventive cardiology, and atherosclerosis. Therapeutic apheresis, its indications and techniques, is a parallel field of investigation. The first on-line survey of the Group has been completed in the first half of 2014. The survey included # 24 Centers in Italy, Germany, Greece, UK, Sweden, Japan and USA. Relevant data have been collected on current practice in diagnosis, therapy and follow-up of dyslipidemias. 240 subjects with hyperlipidemia and treated with lipoprotein apheresis have been reported in the survey, but a large percentage of patients (35%) who could benefit from this therapeutic option are still treated by conventional drug approach. Genetic molecular diagnosis is performed in only 33% of patients while Lipoprotein(a) (Lp(a)) is included in cardiovascular disease risk assessment in 71% of participating Centers. New detailed investigations and prospective multicenter studies are needed to evaluate changes induced by the impact of updated indications and strategies, as well as new treatment options, targeting standardization of therapeutic and diagnostic approaches. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

Published
2015
Full Text
View/download PDF

6. THE OPTIMIZATION OF INTERFERON FOR MS STUDY: 375 MICROG INTERFERON BETA-1B IN SUBOPTIMAL RESPONDERS

Author

Durelli L, Barbero P, Verdun E, Ferrero B, Clerico M, Ricci A, Cucci A, Contessa G, Rivoiro C, Ferrero C, Picco E, Ripellino P, Viglietti D, Bergui M, Zhong JJ, Versino E, Rottoli M, Moroni S, Teatini F, Schoenhuber R, Spissu A, Reggio A, Lo Fermo S, Liberto A, Perla F, Grasso E, Montanari E, Pesci I, Manneschi L, Ghezzi A, Zaffaroni M, Carolei A, Totaro R, Giuliani G, Pucci E, Cartechini E, Scarpini E, Clerici R, Protti A, Erminio C, Cotrufo R, Lus G, Bergamaschi R, Romani A, Bassano MA, Policreti A, Iudice A, Frittelli C, Motti L, Marcello N, Meola G, Robotti M, Cavallo R, Ravetti C, Deotto K., SAVETTIERI, Giovanni, SALEMI, Giuseppe, Durelli L, Barbero P, Verdun E, Ferrero B, Clerico M, Ricci A, Cucci A, Contessa G, Rivoiro C, Ferrero C, Picco E, Ripellino P, Viglietti D, Bergui M, Zhong JJ, Versino E, Rottoli M, Moroni S, Teatini F, Schoenhuber R, Spissu A, Reggio A, Lo Fermo S, Liberto A, Perla F, Grasso E, Montanari E, Pesci I, Manneschi L, Ghezzi A, Zaffaroni M, Carolei A, Totaro R, Giuliani G, Pucci E, Cartechini E, Scarpini E, Clerici R, Protti A, Erminio C, Cotrufo R, Lus G, Savettieri G, Salemi G, Bergamaschi R, Romani A, Bassano MA, Policreti A, Iudice A, Frittelli C, Motti L, Marcello N, Meola G, Robotti M, Cavallo R, Ravetti C, and Deotto K

Subjects
Adult, medicine.medical_specialty, Time Factors, Adolescent, Injections, Subcutaneous, suboptimal treatment response, Gastroenterology, Drug Administration Schedule, law.invention, Young Adult, Multiple Sclerosis, Relapsing-Remitting, Adjuvants, Immunologic, Randomized controlled trial, law, Internal medicine, medicine, Humans, Single-Blind Method, Prospective Studies, Adverse effect, Prospective cohort study, interferon beta (IFNβ), immunomodulatory drug, Subclinical infection, Dose-Response Relationship, Drug, business.industry, Interferon beta-1b, Interferon-beta, Middle Aged, Magnetic Resonance Imaging, Confidence interval, Surgery, Clinical trial, Treatment Outcome, Neurology, Relative risk, multiple sclerosi, MRI activity, Settore MED/26 - Neurologia, Neurology (clinical), business, Follow-Up Studies
Abstract

We aimed to evaluate the safety and MRI efficacy of interferon beta-1b (IFNbeta-1b) 375 microg (subcutaneously [sc] every other day [eod]) in relapsing-remitting multiple sclerosis (RRMS) patients with a suboptimal response to IFNbeta-1b 250 microg, i.e., with MRI activity or relapses. The OPTimization of Interferon for MS (OPTIMS) study was a prospective multicenter randomized phase 2 trial comprising a 6-month run-in phase (to identify suboptimal responders) and a 6-month randomized phase of open-label clinical and blinded MRI follow-up. During run-in all patients were treated with IFNbeta-1b 250 microg sc eod; during the study phase suboptimal treatment responders were randomized either to IFNbeta-1b 250 or 375 microg sc eod. Primary outcome was the proportion of patients without MRI activity during study Months 9-12 according to the intention-to-treat principle. 216 RRMS patients entered the study: 83 suboptimal responders were identified and randomized, 7 refused to continue treatment, 76 were included in the analysis. More patients treated with 375 microg had no MRI activity at Months 9-12 (30/36 vs.16/40; relative risk, 0.28; 95 % confidence interval, 0.08-0.47; p = 0.0001). Sensitivity analysis ("worst case scenario") confirmed the results. No new or unexpected adverse events were observed, but there was a trend towards more withdrawals in the 375 microg group. Increasing the dose of IFNbeta-1b from 250 microg to 375 microg is a successful strategy for reducing subclinical signs of disease activity in RRMS patients. Further studies are needed to show whether this dose may also improve clinical efficacy.

Published
2008

7. MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis

Author

DURELLI L, BARBERO P, BERGUI M, VERSINO E, BASSANO MA, VERDUN E, RIVOIRO C, FERRERO C, PICCO E, RIPELLINO P, GIULIANI G, MONTANARI E, CLERICO M, ITALIAN MULTIPLE SCLEROSIS STUDY GROUP DURELLI L, FERRERO B, PIPIERI A, RICCI A, CUCCI A, FESTA E, ROVERA A, TAVELLA A, CONTESSA G, DELFICO L, ZHONG JJ, ROTTOLI M, MORONI S, TEATINI F, SCHOENHUBER R, SPISSU A, REGGIO A, LO FERMO S, LIBERTO A, PERLA F, GRASSO E, PESCI I, MANNESCHI L, GHEZZI A, ZAFFARONI M, CAROLEI A, TOTARO R, PUCCI, Enzo, CARTECHINI E, SCARPINI E, CLERICI R, PROTTI A, ERMINIO C, COTRUFO R, LUS G, SAVETTIERI, Giovanni, SALEMI, Giuseppe, BERGAMASCHI R, ROMANI A, POLICRETI A, IUDICE A, FRITTELLI C, MOTTI L, MARCELLO N, MEOLA G, ROBOTTI M, CAVALLO R, RAVETTI C, DEOTTO L., DURELLI L, BARBERO P, BERGUI M, VERSINO E, BASSANO MA, VERDUN E, RIVOIRO C, FERRERO C, PICCO E, RIPELLINO P, GIULIANI G, MONTANARI E, CLERICO M, ITALIAN MULTIPLE SCLEROSIS STUDY GROUP DURELLI L, FERRERO B, PIPIERI A, RICCI A, CUCCI A, FESTA E, ROVERA A, TAVELLA A, CONTESSA G, DELFICO L, ZHONG JJ, ROTTOLI M, MORONI S, TEATINI F, SCHOENHUBER R, SPISSU A, REGGIO A, LO FERMO S, LIBERTO A, PERLA F, GRASSO E, PESCI I, MANNESCHI L, GHEZZI A, ZAFFARONI M, CAROLEI A, TOTARO R, PUCCI E, CARTECHINI E, SCARPINI E, CLERICI R, PROTTI A, ERMINIO C, COTRUFO R, LUS G, SAVETTIERI G, SALEMI G, BERGAMASCHI R, ROMANI A, POLICRETI A, IUDICE A, FRITTELLI C, MOTTI L, MARCELLO N, MEOLA G, ROBOTTI M, CAVALLO R, RAVETTI C, and DEOTTO L

Subjects
Male, Neutralising antibody, MULTICENTER, PLACEBO-CONTROLLED TRIAL, GUIDELINES, Gastroenterology, DOUBLE-BLIND, Interferon β, MAGNETIC-RESONANCE, Prospective Studies, Neurologic Examination, biology, Brain, IMPAIRMENT, Middle Aged, Predictive value, Magnetic Resonance Imaging, Recombinant Proteins, Psychiatry and Mental health, Treatment Outcome, Settore MED/26 - Neurologia, Female, Antibody, Interferon beta-1b, Adult, medicine.medical_specialty, DIAGNOSTIC-CRITERIA, Injections, Subcutaneous, Antibodies, Drug Administration Schedule, Disease activity, Multiple Sclerosis, Relapsing-Remitting, Adjuvants, Immunologic, Neutralization Tests, Internal medicine, medicine, Humans, Interferon beta, business.industry, Multiple sclerosis, DISABILITY, MS, Interferon-beta, medicine.disease, Confidence interval, Surgery, biology.protein, Neurology (clinical), business, Follow-Up Studies
Abstract

Objective: To prospectively validate MRI activity and neutralising anti-interferon antibody (NAb) during the first 6 months of interferon β treatment as response indicators in multiple sclerosis (MS). Methods: Patients with relapsing–remitting MS were followed during the first 2 years of treatment. Neurological assessments were performed every 3 months or when a relapse was suspected. MRI scans performed at baseline and at 3, 4, 5 and 6 months after the start of treatment were assessed centrally for disease activity: new T2 or gadolinium enhancing T1 lesions. NAb were assessed using the MxA protein assay; positivity was defined as two consecutive titres ⩾20 NU/ml. We evaluated the predictivity of an active scan, NAb positivity, or both, during the first 6 months of treatment, on the occurrence of clinical disease activity in the following 18 months. Results: 147 patients were assessed at 16 centres. Predictivity parameters (with confidence intervals) were as follows: active scan, sensitivity (SN) 52% (34–69%), specificity (SP) 80% (65–91%), negative predictive value (NPV) 73% (58–77%), positive predictive value (PPV) 62% (42–79%), p = 0.002; NAb positivity, SN 71% (45–88%), SP 66% (55–76%), NPV 92% (82–97%), PPV 29% (16–45%), p = 0.01; active scan and NAb positivity, SN 71% (38–91%), SP 86% (73–94%), NPV 94% (86–98%), PPV 50% (29–70%), p = 0.0003. Conclusions: MRI activity and NAb occurrence during the first 6 months of interferon β treatment were reliable predictors of long term clinical response, particularly when combined. Patients with negative predictors showed a less than 10% risk of developing clinical activity. Patients with positive predictors showed a 50% risk of further clinical activity. These patients need to be followed carefully with further MRI and NAb tests.

Published
2008

8. Actor-driven workflow execution in distributed environments

Author

Berretz, F., Skorupa, S., Sander, V., Belloum, A., Bubak, M., Guarracino, M.R., Vivien, F., Larsson Träff, J., Cannataro, M., Danelutto, M., Hast, A., Perla, F., Knüpfer, A., Di Martino, B., Alexander, M., Computational Science Lab (IVI, FNWI), and System and Network Engineering (IVI, FNWI)

Subjects
Service (systems architecture), Computer science, business.industry, media_common.quotation_subject, Distributed computing, Perspective (graphical), Grid, Task (project management), Workflow, Resource (project management), Software engineering, business, Autonomy, Workflow management system, media_common
Abstract

Currently, most workflow management systems (WfMS) in Grid environments provide push-oriented task distribution strategies, where tasks are directly bound to suitable resources. In those scenarios the dedicated resources execute the submitted tasks according to the request of a WfMS or sometimes by support of a Meta-Scheduling service. This approach has specific problems, especially because of various conditions and constrains that have to be taken into account like local policies or the sites’ autonomy. To deal with such issues, this paper takes a closer look to the task distribution strategies. The established Grid WfMSs essentially support control-flow and data perspectives. However, they neglect the resource perspective. This paper exposes the advantages to deal with this perspective and demonstrates its feasability by a prototype implementation that integrates the missing resource patterns into UNICORE.

Published
2011

9. Multicenter case-control study on restless legs syndrome in multiple sclerosis: The REMS Study

Author

Rems, Italian Study Group, Manconi M, Ferini-Strambi L, Filippi M, Bonanni E, Iudice A, Murri L, Gl, Gigli, Fratticci L, Merlino G, Terzano G, Granella F, Parrino L, Silvestri R, Aricò I, Dattola V, Russo G, Luongo C, Cicolin A, Tribolo A, Cavalla P, Savarese M, Trojano M, Ottaviano S, Cirignotta F, Simioni V, Salvi F, Mondino F, Perla F, Chinaglia G, Zuliani C, Cesnik E, Enrico Granieri, Placidi F, Mg, Palmieri, Manni R, Terzaghi M, Bergamaschi R, Rocchi R, Ulivelli M, Bartalini S, Ferri R, Lo Fermo S, Ubiali E, Viscardi M, Rottoli M, Nobili L, Protti A, Ferrillo F, Allena M, Mancardi G, Guarnieri B, Londrillo F, Manconi, M, FERINI STRAMBI, Luigi, Filippi, Massimo, Bonanni, E, Iudice, A, Murri, L, Gigli, Gl, Fratticci, L, Merlino, G, Terzano, G, Granella, F, Parrino, L, Silvestri, R, Arico, I, Dattola, V, Russo, G, Luongo, C, Cicolin, A, Tribolo, A, Cavalla, P, Savarese, M, Trojano, M, Ottaviano, S, Cirignotta, F, Simioni, V, Salvi, F, Mondino, F, Perla, F, Chinaglia, G, Zuliani, C, Cesnik, E, Granieri, E, Placidi, F, Palmieri, Mg, Manni, R, Terzaghi, M, Bergamaschi, R, Rocchi, R, Ulivelli, M, Bartalini, S, Ferri, R, Lo Fermo, S, Ubiali, E, Viscardi, M, Rottoli, M, Nobili, L, Protti, A, Ferrillo, F, Allena, M, Mancardi, G, Guarnieri, B, and Londrillo, F.

Subjects
Male, demography, trazodone, insomnia, amitriptyline, Comorbidity, Relapsing-Remitting, Sleep medicine, Hypnotic, alprazolam, Restless legs syndrome, multiple sclerosis, sleep, Sleep Initiation and Maintenance Disorders, Insomnia, citalopram, Prospective Studies, Prospective cohort study, diazepam, lorazepam, prazepam, zolpidem, adult, article, blood examination, clinical trial, controlled study, disease course, disease duration, disease severity, female, health survey, human, major clinical study, male, multicenter study, priority journal, restless legs syndrome, risk factor, Adult, Case-Control Studies, Cross-Sectional Studies, Female, Health Surveys, Humans, Italy, Middle Aged, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting, Restless Legs Syndrome, Chronic Progressive, Settore MED/26 - Neurologia, Sleep onset, medicine.symptom, medicine.medical_specialty, Multiple Sclerosis, medicine.drug_class, Multiple sclerosis, Sleep, NO, Physiology (medical), Internal medicine, mental disorders, medicine, Multiple Sclerosis and Restless Legs Syndrome, diagnosis/epidemiology, business.industry, medicine.disease, Adult, Case-Control Studies, Comorbidity, Cross-Sectional Studies, Female, Health Surveys, Humans, Italy, Male, Middle Aged, Multiple Sclerosis, diagnosis/epidemiology, Multiple Sclerosis, diagnosis/epidemiology, Prospective Studies, Restless Legs Syndrome, diagnosis/epidemiology, Sleep Initiation and Maintenance Disorders, Physical therapy, Neurology (clinical), business
Abstract

Study objectives: To verify the existence of a symptomatic form of restless legs syndrome (RLS) secondary to multiple sclerosis (MS) and to identify possible associated risk factors. Design: Prospective, multicenter, case-control epidemiologic survey. Settings: Twenty sleep centers certified by the Italian Association of Sleep Medicine. Patients: Eight hundred and sixty-one patients affected by MS and 649 control subjects. Interventions: N/A. Measures and results: Data regarding demographic and clinical factors, presence and severity of RLS, the results of hematologic tests, and visual analysis of cerebrospinal magnetic resonance imaging studies were collected. The prevalence of RLS was 19% in MS and 4.2% in control subjects, with a risk to be affected by RLS of 5.4 (95%confidence interval: 3.56-8.26) times greater for patients with MS than for control subjects. In patients with MS, the following risk factors for RLS were significant: older age; longer MS duration; the primary progressive MS form; higher global, pyramidal, and sensory disability; and the presence of leg jerks before sleep onset. Patients with MS and RLS more often had sleep complaints and a higher intake of hypnotic medications than patients with MS without RLS. RLS associated with MS was more severe than that of control subjects. Conclusions: RLS is significantly associated with MS, especially in patients with severe pyramidal and sensory disability. These results strengthen the idea that the inflammatory damage correlated with MS may induce a secondary form of RLS. As it does in idiopathic cases, RLS has a significant impact on sleep quality in patients with MS; therefore, it should be always searched for, particularly in the presence of insomnia unresponsive to treatment with common hypnotic drugs.

Catalog

Books, media, physical & digital resources
See catalog results